Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Enfortumab Vedotin Treatment for Metastatic Squamous Cell Carcinoma of the Penis

NCT06104618 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06104618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06104618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Enfortumab Vedotin Treatment for Metastatic Squamous Cell Carcinoma of the Penis
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
December 21, 2023
Completion date
June 1, 2028
Enrollment
28 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic penile squamous cell carcinoma, stage iii penile cancer ajcc v8, stage iv penile cancer ajcc v8, unresectable penile squamous cell carcinoma